Strategic Review: Antibody Innovation Meets Gene Editing and RNA Technology
Regeneron Pharmaceuticals has leveraged its VelociSuite antibody platform to become a leader in ophthalmology, oncology, and immunology. Over the last decade, it has expanded into gene editing, RNA interference, and auditory gene therapy through key partnerships and acquisitions.
Major Deals and Collaborations
- 2016: Adicet Bio (CAR-T cell therapies, early-stage collaboration)
- 2018: Alnylam Pharmaceuticals (RNAi drug development partnership)
- 2019: Isis Pharmaceuticals (antisense RNA drugs)
- 2020: Intellia Therapeutics (CRISPR/Cas9 for liver and muscle diseases)
- 2020: Checkmate Pharmaceuticals (immuno-oncology adjuvants)
- 2021: REGENXBIO (AAV platform for ophthalmic gene therapies)
- 2022: Decibel Therapeutics (gene therapy for hearing loss, collaboration)
- 2023: Molecular Partners (DARPins for immuno-oncology and ophthalmology)
- 2024: Decibel Therapeutics (fully acquired to strengthen ENT pipeline)
Strategic Significance
While known for its antibody platform, Regeneron has been actively integrating cutting-edge technologies like CRISPR (via Intellia), RNAi (via Alnylam), and AAV (via REGENXBIO). Its focus on ophthalmology and hearing loss gene therapies reflects a pivot toward long-term biologics expansion.
My Insight
Regeneron exemplifies a balanced strategy—building internally while embracing external innovations. Its investments in gene editing and precision biologics show a bold move beyond antibody science to future-ready therapies.
Comments